DotBio's platform and validated module library are available for licensing, co-development, NewCo formation, and out-licensing. We have closed deals worth over USD 200M and are actively seeking new pharma and biotech partnerships.
License DotBio's DotBody technology to enhance your existing antibody pipeline. Add DotBody modules to your monoclonal antibodies to create next-generation bi- or tri-specific formats — validated clinical safety profile, 5–10 g/L yields, single Protein A purification.
License validated preclinical or clinical-stage assets from DotBio's pipeline. DB007 (IND-enabling), DB009 (intracellular, lead optimization), DB013 (wet AMD), and DB015 (RA/AS) are available for regional or global licensing.
Joint development of bi- or tri-specific antibody assets against your targets of interest — using DotBio's existing module library or generating new modules (available in ~4 months). DotBio provides the platform; you provide target expertise and clinical infrastructure.
Form a new entity with DotBio around a specific therapeutic area, indication, or asset class. DotBio contributes platform IP and scientific expertise; partner contributes capital, clinical infrastructure, and commercial capabilities.
In January 2022, DotBio out-licensed an anti-VEGF DotBody module to Junshi Biosciences (TopAlliance) for use in developing next-generation multi-specific oncology antibodies. The resulting asset, JS207 (PD1 × VEGFA bispecific), is now in Phase II clinical trials.
DotBio's modular DotBody platform enabled rapid generation of JS207 — now delivering compelling Phase II results.
Ready-to-license DotBody binders against checkpoints, tumor targets, cytokines, and intracellular proteins.
We can generate and validate DotBody modules against your targets of interest in approximately 4 months.
96 multi-specific prototypes per week, tested in high-throughput immune-oncology assays to identify best candidates.
5–10 g/L yields, single Protein A purification, excellent SEC profiles. No manufacturing re-engineering needed.
Human germline with 0.1% ADA in clinic (Herceptin, Avastin lineage). Patent granted US, EU, Japan.
Active China development team, established relationships with CROs and regulatory bodies. Patent pending CN.
Contact us to discuss your targets, therapeutic areas, and partnership structure. We typically respond within 48 hours.